The proportion of nervonic acid in serum lipids is associated with serum Plasmalogen levels and Metabolic Syndrome

Journal of Oleo Science

Volumn 63, Issue 5, 2014, Pages 527-537

  Yamazaki, Yuya ^a   Kondo, Kazuya ^a   Maeba, Ryouta ^b   Nishimukai, Megumi ^c,d   Nezu, Toru ^a   Hara, Hiroshi ^c  

^a ADEKA CORPORATION   (Japan)

^b TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

^d IWATE UNIVERSITY   (Japan)

Author keywords

Metabolic syndrome; Nervonic acid; Peroxisomal dysfunction; Plasmalogen; Very long chain fatty acid

Indexed keywords

BIOCHEMISTRY; CELL MEMBRANES; CHAINS; CHOLESTEROL; LIPOPROTEINS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLISM; PHOSPHOLIPIDS; SATURATED FATTY ACIDS;

METABOLIC SYNDROMES; NERVONIC ACIDS; PEROXISOMAL DYSFUNCTION; PLASMALOGEN; VERY LONG-CHAIN FATTY ACIDS;

BODY FLUIDS;

15 TETRACOSENOIC ACID; ANTIOXIDANT; BEHENIC ACID; FATTY ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIGNOCERIC ACID; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOUNSATURATED FATTY ACID; PLASMALOGEN; TRIACYLGLYCEROL;

ADULT; AGED; AGING; ARTICLE; ATHEROSCLEROSIS; BIOSYNTHESIS; BLOOD; CHEMISTRY; ENDOPLASMIC RETICULUM STRESS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ISOLATION AND PURIFICATION; MALE; MASS FRAGMENTOGRAPHY; METABOLIC SYNDROME X; MIDDLE AGED; OXIDATION REDUCTION REACTION; PEROXISOME; PHYSIOLOGY;

ADULT; AGED; AGING; ANTIOXIDANTS; ATHEROSCLEROSIS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENDOPLASMIC RETICULUM STRESS; FATTY ACIDS; FATTY ACIDS, MONOUNSATURATED; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OXIDATION-REDUCTION; PEROXISOMES; PLASMALOGENS; TRIGLYCERIDES;

EID: 84899444092     PISSN: 13458957     EISSN: 13473352     Source Type: Journal    
DOI: 10.5650/jos.ess13226     Document Type: Article

References (40)

1. Braverman, N. E.; Moser, A. B. Functions of plasmalo-gen lipids in health and disease. Biochem. Biophys. Acta 1822, 1442-1452 (2012).
2. Wallner, S.; Schmitz, G. Plasmalogens the neglected regulatory and scavenging lipid species. Chem. Phys. Lipids 164, 573-589(2011).
3. Colas, R.; Sassolas, A.; Guichardant, M.; Cugnet-An-ceau, C; Moret, M.; Moulin, P.; Lagarde, M.; Calzada, C. LDL from obese patients with the metabolic syndrome show increased lipid peroxidation and activate platelets. Diabetologia 54, 2931-2940 (2011).
4. Stenvinkel, P.; Diczfalusy, U.; Lindholm, B.; Heimbürg-er, O. Phospholipid plasmalogen, a surrogate marker of oxidative stress, is associated with increased cardiovascular mortality in patients on renal replacement therapy. Nephrol. Dial. Transplant. 19, 972-976 (2004).
5. Graessler, J.; Schwudke, D.; Schwarz, P. E.; Herzog, R.; Shevchenko, A.; Bornstein, S. R. Top-down lipidomics reveals ether lipid deficiency in blood plasma of hypertensive patients. PloS One 4, e6261 (2009).
6. Maeba, R.; Maeda, T.; Kinoshita, M.; Takao, K.; Takena-ka, H.; Kusano, J.; Yoshimura, N.; Takeoka, Y.; Yasuda, D.; Okazaki, T.; Teramoto, T. Plasmalogens in human serum positively correlate with high-density lipoprotein and decrease with aging. J. Atheroscler Thromb. 14, 12-18(2007).
7. Zoeller, R. A.; Lake, A. C.; Nagan, N.; Gaposchkin, D. P.; Legner, M. A.; Lieberthal, W. Plasmalogens as endogenous antioxidants: somatic cell mutants reveal the importance of vinyl ether. Biochem. J. 338, 769-776 (1999).
8. Hahnel, D.; Thiery, J.; Brosche, T.; Engelmann, B. Role of plasmalogens in the enhanced resistance of LDL to copper-induced oxidation after LDL apheresis. Arte-rioscler Thromb. Vasc. Biol. 19, 2431-2438(1999).
9. Maeba, R.; Ueta, N. Ethanolamine plasmalogens prevent the oxidation of cholesterol by reducing the oxidizability of cholesterol in phospholipid bilayers. J. Lipid Res. 44, 164-171(2003).
10. Honsho, M.; Asaoku, S.; Fujiki, Y Posttranslational regulation of fatty acyl-CoA reductase 1, Far1, controls ether glycerophospholipid synthesis. J. Biol. Chem. 285, 8537-8542 (2010).
11. Hayashi, H.; Hara, M. 1-Alkenyl group of ethanolamine plasmalogen derives mainly from de novo-synthesized fatty alcohol within peroxisomes, but not extraperoxi-somal fatty alcohol or fatty acid. J. Biochem. 121, 978-983(1997).
12. Wei, H; Kemp, S; McGuinness M. C.; Moser, A. B.; Smith, K.D. Pharmacological induction of peroxisomes in peroxisome biogenesis disorders. Ann. Neurol. 47, 286-296(2000).
13. Schedin, S; Sindelar, P. J; Pentchev, P; Brunk, U; Dall-ner, G. Peroxisomal impairment in Niemann-Pick type C disease. J. Biol. Chem. 272, 6245-6251 (1996).
14. Sandhir, R; Khan, M; Chahal, A; Singh, I. Localization of nervonic acid P-oxidation in human and rodent peroxisomes: impaired oxidation in Zellweger syndrome and X-linked adrenoleukodystrophy. J. Lipid Res. 39, 2161-2171(1998).
15. Wanders, R. J. A.; Waterham, H. R. Peroxisomal disorders: The single peroxisomal enzyme deficiencies. Biochem. Biophys. Acta 1763, 1717-1720(2006).
16. Kou, J.; Kovacs, G. G.; Hoftberger, R.; Kulik, W.; Brodde, A.; Forss-Petter, S.; Honigschnabl, S.; Gleiss, A.; Brugger, B.; Wanders, R.; Just, W.; Budka, H.; Jung-wirth, S.; Fischer, P.; Berger, J. Peroxisomal alterations in Alzheimer's disease. Acta Neuropathol. 122, 271-283(2011).
17. Nordgren, M.; Fransen, M. Peroxisomal metabolism and oxidative stress. Biochimie, in press.
18. Perichon, R.; Bourre, J. M.; Kelly, J. F; Roth, G. S. The role of peroxisomes in aging. Cell. Mol. Life Sci. 54, 641-652(1988).
19. Antoku, Y; Tsukamoto, K; Miyoshi, Y; Nagino, H.; An-ezaki, M.; Suwa, K; Narabe, Y Correlations of elevated levels of hexacosanoate in erythrocyte membranes with risk factors for atherosclerosis. Atherosclerosis 153, 169-173(2000).
20. Kume, A.; Miyazaki, T.; Kitamura, Y; Oshida, K.; Yanagisawa, N.; Takizawa, H.; Fujii, K.; Kiyanagi, T; Sumiyoshi, K; Ohmura, H.; Mokuno, H.; Shimada, K; Daida, H. High levels of saturated very long-chain fatty acid (hexacosanoic acid; C26:0)in whole blood are associated with metabolic syndrome in Japanese men. Diabetes Res. Clin. Pract. 80, 259-264(2008).
21. Lepage, G.; Roy, C. C. Improved recovery of fatty acid through direct transesterification without prior extraction or purification. J. Lipid Res. 25, 1391-1396 (1984).
22. Takemoto, Y; Suzuki, Y; Horibe, R.; Shimozawa, N.; Wanders, R. J. A.; Kondo, N. Gas chromatography/ mass spectrometry analysis of very long chain fatty acids, docosahexaenoic acid, phytanic acid and plasmalogen for the screening of peroxisomal disorders. Brain Dev-Jpn. 25, 481-487(2003).
23. 125I3~). Anal. Biochem. 331, 169-176(2004).
24. Maeba, R.; Yamazaki, Y; Nezu, T; Okazaki, T. Improvement and validation of 125I-high-performance liquid chromatography method for determination of total human serum choline and ethanolamine plasmalogens. Ann. Clin. Biochem. 49, 86-93(2012).
25. Hui, S. P.; Chiba, H.; Kurosawa, T. Liquid chromatogra-phymass spectrometric determination of plasmalo-gens in human plasma. Anal. Bioanal. Chem. 400, 1923-1931(2011).
26. Nishimukai, M.; Yamashita, M.; Watanabe, Y.; Yamazaki, Y.; Nezu, T.; Maeba, R.; Hara, H. Lymphatic absorption of choline plasmalogen is much higher than that of ethanolamine plasmalogen in rats. Eur. J. Nutr. 50, 427-436(2011).
27. Zemski Berry, K. A.; Murphy, R. C. Electrospray ionization tandem mass spectrometry of glycerophospho-ethanolamine plasmalogen phospholipids. J. Am. Soc Mass Spectrom. 15, 1499-1508(2004).
28. Norris, C; Fong, B.; MacGibbon, A.; McJarrow, P. Analysis of phospholipids in rat brain using liquid chroma-tography-mass spectrometry. Lipids 44, 1047-1054 (2009).
29. Nikolic, D.; Katsiki, N.; Montalto, G.; Isenovic, E. R.; Mikhailidis, D. P.; Rizzo, M. Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches. Nutrients 5, 928-948 (2013).
30. Kemp, S.; Valianpour, F.; Denis, S.; Ofman, R.; Sanders, R. J.; Mooyer, P.; Barth, P. G.; Wanders, R. J. A. Elongation of very long-chain fatty acids is enhanced in X-linked adrenoleukodystrophy. Mol. Genet. Metab. 84, 144-151(2005).
31. Moser, H. W.; Moser, A. B.; Hollandsworth, K.; Brere-ton, N. H.; Raymond, G. V. Lorenzo's oil therapy for X-linked adrenoleukodystrophy: rationale and current assessment of efficacy. J. Mol. Neurosci. 33, 105-113 (2007).
32. Koike, R.; Tsuji, S.; Ohno, T.; Suzuki, Y; Orii, T.; Mi-yatake, T. Physiological significance of fatty acid elongation system in adrenoleukodystrophy J. Neurol. Sci. 103, 188-194(1991).
33. Jakobsson, A.; Jörgensen, J. A.; Jacobsson, A. Differential regulation of fatty acid elongation enzymes in brown adipocytes implies a unique role for Elovl3 during increased fatty acid oxidation. Am. J. Physiol. Endocrinol. Metab. 289, E517-E526(2005).
34. Vluggens, A.; Andreoletti, P.; Viswakarma, N.; Jia, Y; Matsumoto, K; Kulik, W.; Khan, M.; Huang, J.; Guo, D.; Yu, S.; Sarkar, J.; Singh, I.; Rao, M. S.; Wanders, R. J.; Reddy, J. K; Cherkaoui-Malki, M. Functional significance of the two ACOX1 isoforms and their crosstalks with PPARa and RXRa. Lab. Invest. 90, 696-708 (2010).
35. Faust, P. L.; Kovacs, W. J. Cholesterol biosynthesis and ER stress in peroxisome deficiency. Biochimie pii: S0300-9084(13)00390-8. Doi(2013).
36. Hotamisligil, G. S. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 140, 900-917(2010).
37. Maeba, R.; Hara, H.; Ishikawa, H.; Hayashi, S.; Yo-shimura, N.; Kusano, J.; Takeoka, Y; Yasuda, D.; Oka-zaki, T.; Kinoshita, M.; Teramoto, T. Myo-inositol treatment increases serum plasmalogens and decreases small dense LDL, particularly in hyperlipidemic subjects with metabolic syndrome. J. Nutr. Sci. Vitamin-ol. 54, 196-202(2008).
38. Bismuth, J.; Lin, P.; Yao, Q.; Chen, C. Ceramide: a common pathway for atherosclerosis? Atherosclerosis 96, 497-504(2008).
39. Yamazaki, Y; Nezu, T.; Maeba, R.; Nishimukai, M.; Hara H. Jpn Pat., 2009-62364 (2008).
40. Wanders, R. J. Peroxisomes, lipid metabolism, and peroxisomal disorders. Mol. Genet. Metab. 83, 16-27 (2004).